Advanced Cardiovascular Systems, Inc. develops and manufactures cardiovascular medical products. It operates as a subsidiary of Abbott Laboratories. Its medical devices help patients with heart diseases in returning to active and productive lives and physicians for improving patient management and clinical outcomes. Advanced Cardiovascular Systems, Inc. is based in Santa Clara, California. it is currently known as Abbott Cardiovascular Systems.

RetroVascular, Inc. is a research and development firm that promotes new treatment methods and medical devices for physicians. The company was founded on April 14, 2006 and is headquartered in Pleasanton, CA.

W. L. Gore & Associates has made its name by creating innovative, technology-driven solutions, from medical devices that treat aneurysms to high-performance GORE‑TEX® fabrics. A privately held company with annual sales of more than $3 billion, Gore is committed to perpetuating its 50-plus year tradition of product innovation. Gore focuses its efforts in four main areas: electronics, fabrics, industrial and medical products. The company’s electronic products division develops and manufactures high-performance copper and optical signal transmission products. Gore’s fabrics provide protection from the elements and enable wearers to remain comfortable across a broad range of activities and conditions. The products made by Gore’s industrial division meet diverse contamination control and processing challenges throughout industry. Implants from the medical division provide creative healing solutions to complex medical problems. Today, Gore employs more than 10,000 employees, called associates, with manufacturing facilities in the United States, Germany, the United Kingdom, Japan and China, and sales offices around the world.

Prytime MedicalTM Devices, Inc. is a cutting-edge medical device business that designs, develops, and commercializes minimally invasive hemorrhage control solutions. The REBOA Resuscitative Endovascular Balloon Occlusion of the Aorta is a minimally invasive procedure that uses a balloon catheter to temporarily occlude major arteries in support of hemorrhage control.

Emboline, Inc develops cardiovascular embolic protection devices for transcatheter and surgical cardiac procedures. Its portfolio of products include the Emboline Complete Accessible Protection, a technology that offers embolic protection of the arterial bed; and the Emboliner, a conventional embolic deflector to protect just the cerebral arteries. It serves cardiac surgery, cardiopulmonary bypass, interventional cardiology, and interventiional electrophysiology markets. The company was founded by Amir Belson and is headquartered in Santa Cruz, CA.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Keystone Heart aspires to be the world leader in embolic cerebral protection for cardiovascular procedures. To develop and manufacture cerebral protection devices, focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, AF ablation and other structural heart procedures. Cerebral function is the essence of quality of life. Preserving brain reserve throughout medical procedures is a key component to procedural success and patient care.

Sankyo Co., Ltd. engages in the manufacture and sale of pachinko and pachislot machines. It operates through the following segments: Pachinko Machines Business, Pachislot Machines Business, Ball Bearing Supply Systems Business, and Others. The Pachinko Machines Business segment produces and sells pachinko machines, machine gauges and its related parts. The Pachislot Machines Business segment markets pachislot machines and related parts. The Ball Bearing Supply Systems segment sells pachinko and pachislot ball feeders, card system equipment, and parlor-related equipment. The Others segment comprises of mobile content service, real estate, golf club operations, and sells general molding products. The company was established on April 12, 1966 and is headquartered in Tokyo, Japan.

Contego Inc. is committed to Corporate IT Governance. Risk Management and Compliance (IT GRC), Contego is the largest "Single Source" IT GRC Services firm in Canada today. They partner with their clients to identify the most critical risks associated with their business and Information Assets. Contego then provides holistic services and solutions for effective IT risk management, mitigation and compliance management. At Contego, they make it their priority to gain a clear understanding of your organization, your business objectives and regulatory compliance requirements. they partner with you to maintain and manage your risks and compliance and support your security infrastructure. Their Services Practices allow their customers to define their “security posture” by developing policies, procedures and road maps to mitigate risks and maintain and prove compliancy throughout the year.

Shijiazhuang Yiling Pharmaceutical develops, produces, and sells patent medicines. The product portfolio includes traditional medicine, health care products, western formulations, and TCM slices, among others. They supply, introduce advanced equipment and pharmaceutical technology both domestically and internationally, and develop a quality control system.

Hebei Yiling Pharmaceutical Research Institute Co., Ltd., established on 2001-04-19, Business scope includes Chinese patent medicine,Medicine and health products,Traditional Medical Devices,Western medicine,Biological product,Research and Development of Sanitary Dressing;technical consulting,Serve,transfer.(Those requiring special approval shall not operate without approval)

Medtronic Vascular designs and develops technologies for coronary, peripheral, and neurovascular indications. The company’s products include S7 Zipper MX Coronary Stent System, Clo-Sur PAD Nonwoven Hydrophilic Wound Dressing, Launcher Coronary Guide Catheter, and Stormer Over-the-Wire Balloon Dilatation Catheter. The company also offers Bridge Assurant Balloon-Expandable Stent Delivery System, GuardWire Plus Temporary Occlusion and Aspiration System, and S660 Coronary Stent. Medtronic Vascular was incorporated in 1991 and is based in Santa Rosa, California. As of January 29, 1999, Medtronic Vascular operates as a subsidiary of Medtronic.

SCIMED Life Systems is a Manufacturing company.

Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.

Boston Scientific Ltd., part of Boston Scientific Corp., is a British company located in Hemel Hempstead. The firm distributes medical products. It was founded in 1992.\nThe company says this about itself: Boston Scientific Ltd designed, manufactured and sold transvaginal mesh (“TVM”) medical devices that were implanted into thousands of Canadian women for the treatment of Stress Urinary Incontinence (“SUI”) and Pelvic Organ Prolapse (“POP”).

Pulmonx is the global leader in interventional procedures for the treatment of COPD. It develops and markets non-surgical technologies for the assessment and treatment of patients with severe emphysema, a progressive and life-threatening form of COPD. The Pulmonx solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The technology is supported by a compelling body of clinical evidence including over 100 published scientific articles regarding the clinical benefits of Zephyr Valves. FDA granted the Zephyr Valve a ‘breakthrough device’ designation, and in June 2018 Pulmonx received FDA pre-market approval to commercialize our Zephyr Valve. The Zephyr Valve is now commercially available and physicians in more than 25 countries around the world routinely use the Zephyr Valves to improve the lives of patients with severe emphysema, with over 76,000 valves used to treat more than 19,000 patients worldwide to date.